Evommune vs Roivant Sciences
EVMN and ROIV side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How EVMN and ROIV compare
Roivant Sciences is the larger company, worth 103 times as much as Evommune ($28.6B against $277M).
Roivant Sciences grew revenue faster over the last twelve months (102% versus −100% for Evommune).
Roivant Sciences scores higher on the StockData Score (8 against 7 for Evommune), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | EVMN | ROIV |
|---|---|---|
| Size and price | ||
| Market cap | $277M | $28.6B |
| Share price | $7.63 | $39.53 |
| Change, 1 year | −60.9% | 85.4% |
| Change, 5 years | – | 394% |
| Beta (5Y) | 0.79 | 0.85 |
| Employees | 48 | 721 |
| StockData Score | ||
| Total score | 7 | 8 (better) |
| Valuation score | 1 (better) | 0 |
| Growth score | 0 | 1 (better) |
| Performance score | 0 | 1 (better) |
| Health score | 6 | 6 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | – | 695× |
| P/B | 1.1× (better) | 7.1× |
| FCF yield | −32.9% | −0.12% (better) |
| Growth | ||
| Revenue growth (TTM) | −100% | 102% (better) |
| Revenue growth, 5Y average | – | −19.1% |
| Profitability | ||
| Operating margin | – | −1358% |
| Net margin | – | −838% |
| FCF margin | – | −81.2% |
| Return on equity | −331% | −8.2% (better) |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 8.52 | 15.56 (better) |
| Altman Z-score | 3.85 | 45.37 (better) |
| Piotroski F-score | 5 (better) | 2 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 95.4% | 78.1% |
| Held by insiders | 51.6% | 13.9% |
| Insider net buying, 12 months | −$2.1M (better) | −$798M |
| Superinvestors holding | – | 1 |
| Short interest, % of float | 19.3% | 7.3% |
Go deeper
- EVMN stock overview
- EVMN income statement
- EVMN valuation and score
- ROIV stock overview
- ROIV income statement
- ROIV valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.